Professional Profile

I am multifaceted healthcare professional with in-depth experiences in academia, pharmaceutical industry, and healthcare sector. I am a registered clinical pharmacist in Canada, holding a Ph.D. in Oncology from the University of Alberta (2015). Currently, I am a Medical Manager with Roche and seeking to build on and expand my expertise by joining the medical & scientific affairs team at Gilead

Work Authorization

●Canadian Citizen

Certifications and Licenses

●PEBC certified pharmacist

●Valid Canadian Drivers licence

Bold ambition

●Be the difference

Sample Publications

●Mani RS, Mermershtain I, Abdou I, Fanta M, Hendzel MJ, Glover JNM, Weinfeld M. Domain analysis of PNKP/XRCC1 interactions: influence of genetic variants of XRCC1. J Biol Chem. 2018 Nov 16

●Ismail Abdou et al. DNA ligase III acts as a DNA strand break sensor in the cellular orchestration of DNA strand break repair, Nucleic Acids Research (2015), Volume: 43, Issue: 2, Pages 875-92

Professional Experience

Professional Experience

Medical Affairs Manager, Personalized Healthcare (PHC) Roche, (2019-Current)

Aim: Constructing the medical affairs strategies and tactics within the PHC Squad focusing on the simultaneous enablement of the four central pillars of PHC

a)Medical training to Oncology cross-functional team on different genomic profiling platforms, with emphasis on Foundation Medicine portfolio (FoundationOne® Heme, FoundationOne® CDx, & FoundationOne® Liquid CDx)

b)Advisory Boards for regional Therapy Area Experts, encompassing pathologists & medical oncologists to understand current practice for precision Oncology and gain actionable insights

c)Supporting IIS focusing on Precision Oncology to build the hands on experience

d)Conducting with clinical research capability program in partnership with SEHA (major public sector Healthcare provider)

e)Preparation and execution of the medical affairs strategies and tactics for PHC and Foundation Medicine in the UAE

f)Engagement of regional and international speakers in several regional congresses to educate the medical community on Precision Oncology (Agenda & content creation, slide deck preparation, speakers briefing, etc …)

g)Medical review of promotional materials

h)Leading e-Campaigns focusing on the education of healthcare professionals on the value of Foundation Medicine’s testing portfolio & emerging biomarkers and genomic signatures

i)Core team member within global working groups focused on driving strategic pillars to Foundation Medicine testing portfolio which materialized in leading multiple solutions

j)Closely working with cross-functional team members on the inclusion of Foundation Medicine Testing portfolio in DHA & SEHA laboratory services, materializing in two medical requests being raised to DHA & SEHA to include the tests

Sr. MSL, Oncology-Haematology, AstraZeneca, (2017 – 2019)

Aim: Constructing & executing medical affairs strategies and activities covering the Oncology-Haematology therapy areas and product portfolio (Fulvestrant, Olaparib, and Acalabrutinib)

Medical Strategy, tactics, & Implementation:

a)Preparation & execution of medical affairs plans and strategies across different disease areas (haematological malignancies, breast, and ovarian cancers) that encompass pre-& post-launch plans for MCL, CLL, Ovarian Cancer, & Breast Cancer. Those have been incorporated into brands’ BSPs & LRPs, and I have presented them to the company’s senior leadership team & international teams

b)Preparation and execution of prelaunch & post-launch activities for Haematology therapy area, e.g., speaker tours, advisory boards to gain insights on unmet medical needs and current management landscape, KOL mapping, F2F meetings, and roundtable discussions focusing on new drug introduction

c)Providing scientific evidence and support for regulatory submissions and market access value proposition initiatives (Working with the regulatory team on preparation of medical value document as a requirement by UAE & Qatar MOH, and Acalabrutinib has been approved accordingly). Worked with Market Access Team on formulary inclusion of Acalabrutinib in Kuwait Cancer Control Center (Approved)

d)Insights gathering from F2F interactions and sharing with cross-functional team in support of prelaunch and launched products/indications

e)Reviewing and updating medical content for promotional materials

f)Up to date medical training for new hires to ensure readiness encompassing therapy area & product knowledge with a “Go to Market” readiness level

g)Identification of regional clinical research gaps for potential clinical research collaboration

Medical Education:

a)External

(i)Design, speaker selection (regional & international), briefing, & implementation of medical educational standalones in Oncology (focusing on updates in Ovarian & Breast Cancers). In Haematology, I have been organized the first AstraZeneca medical education standalone globally, Gulf Lymphoma Summit (GLS), covering updates in 4 different tumor types in B-cell Non-Hodgkin’s Lymphoma. The meeting has been done in collaboration with the 2 key regional societies (ESH & OSH) and CME accredited (feedback & metrics available upon request)

(ii)ensuring continuous education to HCPs in Oncology & haematology, by organizing speaker tours (5) & MSL led meetings (10), to ensure compliant data dissemination & providing the most recent updates to HCPs in the relevant therapy areas

b)Internal

(i)Leading up to date medical trainings to cross-functional team members, where in Haematology I have designed 6 training modules that are continuously delivered over more than 4 waves to ensure maximum team readiness. The modules have been focusing on therapy area knowledge, product pharmacology, clinical trials, & competitive landscape. I have been conducting similar trainings in Oncology as well

(ii)Providing cross functional team with most recent updates in Oncology & Haematology from international congresses, guidelines, and clinical trials for AZ & competitors’ portfolio during brand team meetings to be able to integrate into business plans

Sr. MSL, Oncology-Haematology, CNS Janssen Pharmaceutica (2016 – 2017)

Aim: Maximize with cross-functional teams the brand value of Janssen Pharmaceutica Oncology-Haematology (Abiraterone Acetate and Ibrutinib) and CNS products (Paliperidone Palmitate)

a)Effective preparation and delivering of scientific presentations to KOLs, demonstrating the value of product portfolio

b)Preparation and submission of scientific summaries to specialty departments in key centers highlighting the current updates in management guidelines and filling the gaps in unmet medical needs

c)Preparation of medical education events including training sessions and scientific meetings

d)Timely responding to medical information requests

e)Introduction of a new medication to assigned territory

f)Liaising with market access team to provide medical information on Paliperidone Palmitate for formulary addition request in key accounts in KSA

g)Conducting ongoing medical education sessions for sales team via L2L program focusing on updates pertaining to therapy areas and products

h)Training for newly hired sales representatives

Research Fellow University of Alberta, Medical Genetics (Feb 2016 – July 2016)

Applying my scientific knowledge in addition to immaculate laboratory experimentation aptitude, my work at Dr. Lehmann’s lab focused on exploring the potential involvement of specific transcription factors in inherited diseases

RPh, Clinical Pharmacist Shoppers Drug Mart, (2014 – 2016)

Aim: Advancing patient care

Impact: Applying my therapeutic expertise and team management skills to work with other healthcare professionals to promote patients’ welfare better

a)Effective and collaborative communication with other healthcare professionals discussing patients’ health-related issues and help in evidence-based decision making

b)Timely responding to inquiries from physicians on updates in management guidelines and feedback on new products

c)Top performer in clinical pharmacy services encompassing medication reviews and care plans

Ph.D. Researcher University of Alberta, Oncology (2009 – 2015)

Aim: Increasing the pool of “druggable” proteins in cancer therapy

Impact: providing a nuanced view on how live cells sense specific type of DNA damage

●Experienced in scholarship and grant proposal writing, awarded the Alberta Cancer Foundation (ACF) graduate studentship (2011-2015) and the Rob Meltzer graduate studentship (2013)

●Mastered oral presentations in scientific conferences to highlight work progress and achievements, awarded the best presentation in the Signal Transduction Research group meeting (2015) and in the Canadian Society for Molecular Biosciences meeting (2012)

●Scholarly writing, preparation, and editing of manuscripts encompassing original research work and review articles, published in peer review journals and recognized by Oncology department at the University of Alberta, received Graduate Achievement award (2015)

Contact this candidate